Cargando…

Inhibition of NRF2 by PIK-75 augments sensitivity of pancreatic cancer cells to gemcitabine

We describe the potential benefit of PIK-75 in combination of gemcitabine to treat pancreatic cancer in a preclinical mouse model. The effect of PIK-75 on the level and activity of NRF2 was characterized using various assays including reporter gene, quantitative PCR, DNA-binding and western blot ana...

Descripción completa

Detalles Bibliográficos
Autores principales:	DUONG, HONG-QUAN, YI, YONG WEON, KANG, HYO JIN, HONG, YOUNG BIN, TANG, WENXI, WANG, ANTAI, SEONG, YEON-SUN, BAE, INSOO
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2013
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3928470/ https://www.ncbi.nlm.nih.gov/pubmed/24366069 http://dx.doi.org/10.3892/ijo.2013.2229

Ejemplares similares

Inhibition of checkpoint kinase 2 (CHK2) enhances sensitivity of pancreatic adenocarcinoma cells to gemcitabine
por: Duong, Hong-Quan, et al.
Publicado: (2013)

Combination of dasatinib and gemcitabine reduces the ALDH1A1 expression and the proliferation of gemcitabine-resistant pancreatic cancer MIA PaCa-2 cells
por: DUONG, HONG-QUAN, et al.
Publicado: (2014)

Aldehyde dehydrogenase 1A1 confers intrinsic and acquired resistance to gemcitabine in human pancreatic adenocarcinoma MIA PaCa-2 cells
por: DUONG, HONG-QUAN, et al.
Publicado: (2012)

Inhibition of the PI3K/AKT pathway potentiates cytotoxicity of EGFR kinase inhibitors in triple-negative breast cancer cells
por: Yi, Yong Weon, et al.
Publicado: (2013)

Brucein D augments the chemosensitivity of gemcitabine in pancreatic cancer via inhibiting the Nrf2 pathway
por: Zhang, Juan, et al.
Publicado: (2022)

HER2 confers drug resistance of human breast cancer cells through activation of NRF2 by direct interaction
por: Kang, Hyo Jin, et al.
Publicado: (2014)

BML-275, an AMPK inhibitor, induces DNA damage, G2/M arrest and apoptosis in human pancreatic cancer cells
por: DUONG, HONG-QUAN, et al.
Publicado: (2012)

Digoxin sensitizes gemcitabine-resistant pancreatic cancer cells to gemcitabine via inhibiting Nrf2 signaling pathway
por: Zhou, Yunjiang, et al.
Publicado: (2019)

Silencing of NRF2 Reduces the Expression of ALDH1A1 and ALDH3A1 and Sensitizes to 5-FU in Pancreatic Cancer Cells
por: Duong, Hong-Quan, et al.
Publicado: (2017)

β-TrCP1 degradation is a novel action mechanism of PI3K/mTOR inhibitors in triple-negative breast cancer cells
por: Yi, Yong Weon, et al.
Publicado: (2015)

CR6-interacting Factor 1 (CRIF1) Regulates NF-E2-related Factor 2 (NRF2) Protein Stability by Proteasome-mediated Degradation
por: Kang, Hyo Jin, et al.
Publicado: (2010)

Suppression of IL-6 Gene by shRNA Augments Gemcitabine Chemosensitization in Pancreatic Adenocarcinoma Cells
por: Xing, Hai-Bo, et al.
Publicado: (2018)

Corrigendum to “Suppression of IL-6 Gene by shRNA Augments Gemcitabine Chemosensitization in Pancreatic Adenocarcinoma Cells”
por: Xing, Hai-Bo, et al.
Publicado: (2022)

BRCA1 and Oxidative Stress
por: Yi, Yong Weon, et al.
Publicado: (2014)

Gold Nanoparticles sensitize pancreatic cancer cells to gemcitabine
por: Huai, Yanyan, et al.
Publicado: (2019)

Interferon-beta enhances sensitivity to gemcitabine in pancreatic cancer
por: Blaauboer, Amber, et al.
Publicado: (2020)

Resveratrol-Induced Downregulation of NAF-1 Enhances the Sensitivity of Pancreatic Cancer Cells to Gemcitabine via the ROS/Nrf2 Signaling Pathways
por: Cheng, Liang, et al.
Publicado: (2018)

The Inhibitory Effect of PIK-75 on Inflammatory Mediator Response Induced by Hydrogen Peroxide in Feline Esophageal Epithelial Cells
por: Jeong, Jun Yeong, et al.
Publicado: (2014)

Brusatol Enhances the Chemotherapy Efficacy of Gemcitabine in Pancreatic Cancer via the Nrf2 Signalling Pathway
por: Xiang, Yukai, et al.
Publicado: (2018)

Intralesional injection of rose bengal augments the efficacy of gemcitabine chemotherapy against pancreatic tumors
por: Innamarato, Patrick, et al.
Publicado: (2021)

Inhibition of Neddylation Modification Sensitizes Pancreatic Cancer Cells to Gemcitabine
por: Li, Hua, et al.
Publicado: (2017)

Gemcitabine plus S-1 for metastatic pancreatic cancer
por: Zhu, Hong, et al.
Publicado: (2018)

The BET Inhibitor JQ1 Augments the Antitumor Efficacy of Gemcitabine in Preclinical Models of Pancreatic Cancer
por: Miller, Aubrey L., et al.
Publicado: (2021)

SLC38A5 Modulates Ferroptosis to Overcome Gemcitabine Resistance in Pancreatic Cancer
por: Kim, Myeong Jin, et al.
Publicado: (2023)

Harmine suppresses the proliferation of pancreatic cancer cells and sensitizes pancreatic cancer to gemcitabine treatment
por: Wu, Lin-Wen, et al.
Publicado: (2019)

Dual inhibition of EGFR and MET induces synthetic lethality in triple-negative breast cancer cells through downregulation of ribosomal protein S6
por: YI, YONG WEON, et al.
Publicado: (2015)

Bmi1 inhibition enhances the sensitivity of pancreatic cancer cells to gemcitabine
por: Yin, Tao, et al.
Publicado: (2016)

Disrupting glutamine metabolic pathways to sensitize gemcitabine-resistant pancreatic cancer
por: Chen, Ru, et al.
Publicado: (2017)

Wogonin increases gemcitabine sensitivity in pancreatic cancer by inhibiting Akt pathway
por: Zhang, Tianli, et al.
Publicado: (2022)

MicroRNA-33a-mediated downregulation of Pim-3 kinase expression renders human pancreatic cancer cells sensitivity to gemcitabine
por: Liang, Chen, et al.
Publicado: (2015)

HEATR1 deficiency promotes pancreatic cancer proliferation and gemcitabine resistance by up-regulating Nrf2 signaling
por: Zhou, Yunjiang, et al.
Publicado: (2019)

Gemcitabine plus concurrent irreversible electroporation vs gemcitabine alone for locally advanced pancreatic cancer
por: Ma, Yang-Yang, et al.
Publicado: (2020)

Ivermectin and gemcitabine combination treatment induces apoptosis of pancreatic cancer cells via mitochondrial dysfunction
por: Lee, Da Eun, et al.
Publicado: (2022)

Pancreatic Cancer Chemoresistance to Gemcitabine
por: Amrutkar, Manoj, et al.
Publicado: (2017)

Complete loss of ATM function augments replication catastrophe induced by ATR inhibition and gemcitabine in pancreatic cancer models
por: Dunlop, Charles R., et al.
Publicado: (2020)

Inhibition of de novo pyrimidine synthesis augments Gemcitabine induced growth inhibition in an immunocompetent model of pancreatic cancer
por: Phan, Thuy, et al.
Publicado: (2021)

Astaxanthin inhibits gemcitabine-resistant human pancreatic cancer progression through EMT inhibition and gemcitabine resensitization
por: Yan, Tao, et al.
Publicado: (2017)

Real-world outcomes of adjuvant gemcitabine versus gemcitabine plus capecitabine for resected pancreatic ductal adenocarcinoma
por: Kang, Sora, et al.
Publicado: (2022)

Synthetic lethal RNAi screening identifies sensitizing targets for gemcitabine therapy in pancreatic cancer
por: Azorsa, David O, et al.
Publicado: (2009)

Enhancing sorafenib-mediated sensitization to gemcitabine in experimental pancreatic cancer through EMAP II
por: Awasthi, Niranjan, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_fkvb4plan1o1f5v2qshsp6emte